Bladder cancer drug trial halted early after only 4 patients
NCT ID NCT05581589
First seen Mar 05, 2026 · Last updated May 15, 2026 · Updated 5 times
Summary
This early-phase trial tested whether a targeted chemotherapy drug (sacituzumab govitecan) given before bladder removal surgery could improve outcomes for people with a rare type of muscle-invasive bladder cancer. The study planned to enroll about 20 participants but was stopped early after only 4 people joined. The main goal was to see if the drug could make the cancer disappear completely by the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE BLADDER CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.